Sunshine Biopharma Inc (SBFM) Gross Profit Margin starting from the second quarter 2026 to second quarter 2025, Profitability Trends and Ranking, Fundamental Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Gross Margin
• EBITDA Margin
• Operating Margin
• Net Margin
• Pre-Tax Margin
• Effective Tax Rate
• Free Cash Flow Margin
• Cash Flow Margin
Sunshine Biopharma Inc   (NASDAQ: SBFM)


Sunshine Biopharma Inc 's Gross Profit Margin by quarter

Trends, Rankings, Statistics


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

SBFM Gross Profit Margin (Jun 30 2026)
Q2 		(Mar 31 2026)
Q1 		(Dec 31 2025)
Q4 		(Sep 30 2025)
Q3 		(Jun 30 2025)
Q2
Y / Y Revenue Change -1.56 %
Seq. Revenue Change 14.53 %
Revenue In Millions $9.26
Gross Profit Margin 26.2 %
Gross Profit Margin Total Ranking # 2632
Gross Profit In Millions $2.43
Y / Y Gross Profit Change -29.1 %
Seq. Gross Profit Change 11.27 %


Commenting Second Quarter 2026 Gross Profit Margin
Sunshine Biopharma Inc has managed to improve its Revenue sequentially to $9.26 millions by 14.53 % faster than Gross Profit increase of 11.27 % to $2.43 millions, this led to contraction in Gross Profit Margin to 26.2 %, below company average.


Observing second quarter 2026 results within Major Pharmaceutical Preparations industry 131 other companies have achieved higher Gross Profit Margin. While Gross Profit Margin overall ranking has deteriorated relative to the three months before, from 2481 to 2632.
Learn about Gross Margin
SBFM's Gross Profit Margin second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 132
Healthcare Sector # 397
Overall # 2612

Gross Profit Margin Statistics
High Average Low
65.92 % 39.09 % 0.05 %
(Jun 30 2020)   (Mar 31 2019)


SBFM Gross Income Trends • More of SBFM's Profitabilty Ratios • SBFM Stock Quotes and Charts


Other Gross Profit Margin Profitability Ratios
SBFM's Cumulative Gross Profit Margin
Major Pharmaceutical Preparations Industry Gross Profit Margin Trends and Statistics
Healthcare Sector Gross Profit Margin Statistics
Gross Profit Margin Profitability Trends for overall market
SBFM's Gross Profit Margin Profitability versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Gross Profit Margin
Lowest Ranking Gross Profit Margin
Gross Profit Margin Profit Margin for SBFM's Competitors
Gross Profit Margin Profit Margin for Sunshine Biopharma Inc 's Suppliers
Gross Profit Margin Profit Margin for SBFM's Customers

You may also want to know
SBFM's Annual Growth Rates SBFM's Profitability Ratios SBFM's Asset Turnover Ratio SBFM's Dividend Growth
SBFM's Roe SBFM's Valuation Ratios SBFM's Financial Strength Ratios SBFM's Gross Profit Growth
SBFM's Roa SBFM's Inventory Turnover Ratio SBFM's Growth Rates SBFM's Dividend Comparisons


Companies with similar Gross Profit Margin in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Gross Profit MarginJun 30 2026 MRQ Gross ProfitJun 30 2026 MRQ Revenue
Bristol myers Squibb Company  71.28 %$ 9,247.000  Millions$ 12,973.000  Millions
Harrow Inc   71.27 %$ 50.363  Millions$ 70.661  Millions
Aquestive Therapeutics Inc   70.93 %$ 9.802  Millions$ 13.819  Millions
Earth Science Tech Inc   69.53 %$ 6.275  Millions$ 9.026  Millions
Omeros Corporation  69.37 %$ 27.731  Millions$ 39.976  Millions
Heron Therapeutics Inc   69.28 %$ 26.094  Millions$ 37.666  Millions
Johnson and Johnson  68.19 %$ 17,259.000  Millions$ 25,310.000  Millions
Evolus Inc   68.00 %$ 57.180  Millions$ 84.084  Millions
Eton Pharmaceuticals Inc   67.61 %$ 25.413  Millions$ 37.589  Millions
Fortress Biotech Inc   67.18 %$ 12.575  Millions$ 18.718  Millions
Citius Pharmaceuticals Inc   67.07 %$ 1.002  Millions$ 1.494  Millions
Citius Oncology Inc  67.07 %$ 1.002  Millions$ 1.494  Millions
Journey Medical Corp  66.81 %$ 12.367  Millions$ 18.510  Millions
IMPACT BIOMEDICAL INC.  66.67 %$ 0.002  Millions$ 0.003  Millions
Ainos Inc   65.13 %$ 0.000  Millions$ 0.000  Millions
Aytu Biopharma Inc  64.63 %$ 10.409  Millions$ 16.106  Millions
Zomedica Corp   63.51 %$ 6.041  Millions$ 9.512  Millions
Longeveron Inc   63.41 %$ 0.182  Millions$ 0.287  Millions
Abeona Therapeutics Inc   63.30 %$ 7.203  Millions$ 11.380  Millions
Ani Pharmaceuticals Inc  62.35 %$ 165.886  Millions$ 266.044  Millions
Polomar Health Services, Inc.  61.22 %$ 0.936  Millions$ 1.529  Millions
Clene Inc   60.00 %$ 0.054  Millions$ 0.090  Millions
Emergent Biosolutions Inc   58.56 %$ 137.200  Millions$ 234.300  Millions
Elanco Animal Health Incorporated  58.33 %$ 798.000  Millions$ 1,368.000  Millions
Siga Technologies Inc  57.17 %$ 23.441  Millions$ 41.002  Millions
Schrodinger Inc   55.07 %$ 32.432  Millions$ 58.889  Millions
Zai Lab Limited  54.70 %$ 58.149  Millions$ 106.311  Millions
Mallinckrodt Plc  54.52 %$ 282.000  Millions$ 517.200  Millions
International Stem Cell Corporation  54.50 %$ 1.458  Millions$ 2.675  Millions
Organon and Co   54.36 %$ 847.000  Millions$ 1,558.000  Millions




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.